Devonian Health Group Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVHGF research report →
About the company
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis.
- CEO
- Andre Boulet
- IPO
- 2022
- Employees
- 6
- HQ
- Québec, QC, CA
Price Chart
- Market Cap
- $19.47M
- P/E
- -4.54
- P/S
- 10.47
- P/B
- 3.95
- EV/EBITDA
- -2.48
- Div Yield
- 0.00%
- Gross Margin
- 58.11%
- Op Margin
- -230.37%
- Net Margin
- -227.68%
- ROE
- -77.36%
- ROIC
- -85.30%
- Revenue
- $17.03M · -4.43%
- Net Income
- $-4,339,852 · -254.38%
- EPS
- $-1.76 · -253.01%
- Op Income
- $-1,027,425
- FCF YoY
- -116.22%
- 52W High
- $10.80
- 52W Low
- $4.27
- 50D MA
- $10.07
- 200D MA
- $7.09
- Beta
- 1.26
- Avg Volume
- 1
Get TickerSpark's AI analysis on DVHGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DVHGF coverage
Recent articles, reports, and earnings notes.
No research on DVHGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DVHGF report →Similar companies
Peers in the same neighborhood.